Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.36 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.36 |
| ▸ | SGPL1 | O95470 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339429 | 1.00 | LPAR3 (0.37) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL339675 | 1.00 | LPAR3 (0.37) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL5663655 | 0.86 | LPAR3 (0.36) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL5673069 | 0.85 | FABP3 (0.41) | LPAR3S1PR1 | |
| SCHEMBL5672161 | 0.82 | LPAR3 (0.34) | LPAR3LPAR1LPAR2P2RY10S1PR1 | |
| SCHEMBL339933 | 0.80 | CDC25A (0.36) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL340043 | 0.80 | CDC25A (0.36) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL338952 | 0.80 | CDC25A (0.36) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL339734 | 0.79 | LPAR3 (0.32) | LPAR3LPAR1LPAR2P2RY10SGPL1 | |
| SCHEMBL339773 | 0.79 | SIGMAR1 (0.38) | LPAR3LPAR1LPAR2P2RY10SGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097752-B2 | Antiprotozoal ring-substituted phospholipids | MAKSCIENTIFIC, LLC (US) | 2012-01-17 | — | — | US | claimed |
| US-8097752-B2 | Antiprotozoal ring-substituted phospholipids | MAKSCIENTIFIC, LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | MAK SCIENTIFIC CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | PHOSPHO1, PLTP, PLA2G2C | LPAR3 109/4885LPAR1 306/4885LPAR2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.